Devika Das, MD, MSHQS, FASCO (@DevikaDasMD) ranks #37 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 7 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6. CMS Open Payments lists $18,205 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #37 · 7 physicians engaged
- CMS Open Payments lists $18,205 in 2025 general payments.
This Month
What Devika Das, MD, MSHQS, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #37 | — | 7 | 9 | Full ranking |
Trials Devika Das, MD, MSHQS, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 1 | #47 of 74 | May 31, 2026 |
Devika Das, MD, MSHQS, FASCO on HARMONi-6
RT @FordePatrick: Impressive results from the phase 3 Harmoni 6 trial of chemotherapy plus ivonescimab or anti-PD1 for advanced squamous lu…
Devika Das, MD, MSHQS, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Verdict for me: Await the global study results for HARMONY 3 before adoption. Majority of our patients with squamous cell lung cancer are older, have significant cavitation. ( in addition to other co morbidities which make the VEGF AEs harder to tolerate) The benefit in the PDL1 negative squamous tumors is intriguing though. 🤔 Congratulations on this study and this is definitely an un met need! 🙏 #lcsm @asco #ASCO26
Practice changing!!! What a memorable plenary and journey for RAS 👏👏👏👏 #PDAC @asco #ASCO26 Can’t wait for the #lcsm data now! 👏👏👏😭 Our patients with pancreas cancer ( and all cancer) deserve precision medicine access! https://t.co/k2lBMl29PK
I am happy to see so many phenomenal abstracts pertaining to #lcsm at #ASCO26 but really excited to see data from DLL-3 targeted CAR-T for r/r small cell and NK cell consolidation therapy. Solid tumor oncology landspace is rapidly moving beyond ADCs for innovation! @ASCO @SclcSMASHERS 👏👏👏
PDL1 negative tumor benefit as seen here #lcsm ( cross trial comparison) https://t.co/mx8lxcFquL
Rural academic thoracic oncology perspective as I am now parsing through the #WCLC26 data #lcsm Great year and momentum for #SCLC 📍 Maverick data is phenomenal to spare patients PCI and cognitive decline but absolutely need access to high quality and timely MRI access ( cumulative brain Mets in the Non PCI cohort was higher) 📍 sequencing therapies and new targets specially with Anti B7-H3 ADC ( and others like SEZ) weaved in with Tarlatamab will likely change the landscape of treatment and survival. Inclusion of rural patients with ECOG 2 in the global trials for these/similar agents is key as our population can be often older, frailer and with more commodities. #TAISHAN-302 #ARTEMIS-008
Industry Payments
CMS Open Payments · 2025 general payments
$18,205 across 40 payments